JP2011037889A5 - - Google Patents

Download PDF

Info

Publication number
JP2011037889A5
JP2011037889A5 JP2010232130A JP2010232130A JP2011037889A5 JP 2011037889 A5 JP2011037889 A5 JP 2011037889A5 JP 2010232130 A JP2010232130 A JP 2010232130A JP 2010232130 A JP2010232130 A JP 2010232130A JP 2011037889 A5 JP2011037889 A5 JP 2011037889A5
Authority
JP
Japan
Prior art keywords
phospholipid
block copolymer
derived
amount
surface modifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010232130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011037889A (ja
JP5539839B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011037889A publication Critical patent/JP2011037889A/ja
Publication of JP2011037889A5 publication Critical patent/JP2011037889A5/ja
Application granted granted Critical
Publication of JP5539839B2 publication Critical patent/JP5539839B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010232130A 1998-03-30 2010-10-15 水不溶性物質のマイクロ粒子を製造するための組成物及び方法 Expired - Fee Related JP5539839B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7980998P 1998-03-30 1998-03-30
US60/079,809 1998-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000540812A Division JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2011037889A JP2011037889A (ja) 2011-02-24
JP2011037889A5 true JP2011037889A5 (enExample) 2012-08-30
JP5539839B2 JP5539839B2 (ja) 2014-07-02

Family

ID=22152962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000540812A Expired - Fee Related JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法
JP2010232130A Expired - Fee Related JP5539839B2 (ja) 1998-03-30 2010-10-15 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000540812A Expired - Fee Related JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Country Status (14)

Country Link
US (1) US6387409B1 (enExample)
EP (1) EP1067914B1 (enExample)
JP (2) JP4709378B2 (enExample)
KR (1) KR100628341B1 (enExample)
CN (1) CN1303278B (enExample)
AT (1) ATE318132T1 (enExample)
AU (1) AU761205B2 (enExample)
CA (1) CA2326456C (enExample)
DE (1) DE69929959T2 (enExample)
ES (1) ES2257041T3 (enExample)
IL (3) IL138765A0 (enExample)
SE (1) SE0003429L (enExample)
TW (1) TWI267383B (enExample)
WO (1) WO1999049846A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
DE69929959T2 (de) * 1998-03-30 2006-11-02 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
HK1042856B (zh) 1998-11-20 2007-07-27 Skyepharma Canada Inc. 可分散的磷脂稳定的微粒
CN1213733C (zh) * 1998-11-20 2005-08-10 斯凯伊药品加拿大公司 制备稳定的不溶性微粒的悬浮液的方法
DE60020382T2 (de) * 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US20040178135A1 (en) * 2003-03-13 2004-09-16 Beplate Douglas K. Filtering device incorporating nanoparticles
MXPA05012467A (es) * 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
EA200600877A1 (ru) * 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
WO2006057429A1 (ja) * 2004-11-24 2006-06-01 Nanocarrier Co., Ltd. ブロックコポリマーのモーフォロジ－の変化方法
BRPI0612071A2 (pt) * 2005-06-14 2010-10-19 Baxter Int formulações farmacêuticas para minimizar interações entre fármacos
WO2007008697A2 (en) * 2005-07-08 2007-01-18 University Of Chicago Compositions and methods for refolding of denatured proteins
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
CN103228266B (zh) 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
WO2014004507A1 (en) * 2012-06-27 2014-01-03 Shell Oil Company Fuel and engine oil composition and its use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
ATE198148T1 (de) * 1995-02-06 2001-01-15 Elan Pharma Int Ltd Formulierungen von verbindungen als nanopartikel dispergiert in verdaubaren ölen oder fettsäuren
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
WO1997014407A1 (en) * 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
JP2000516244A (ja) * 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
DE69929959T2 (de) * 1998-03-30 2006-11-02 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
KR20140029532A (ko) * 2011-09-30 2014-03-10 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 스퍼터링 타깃 및 그 제조 방법

Similar Documents

Publication Publication Date Title
JP2011037889A5 (enExample)
JP2002509876A5 (enExample)
Salzano et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
Gao et al. Polymeric capsule-cushioned leukocyte cell membrane vesicles as a biomimetic delivery platform
JP2018188443A (ja) 癌を処置するための組成物および該組成物を製造するための方法
CL2013003621A1 (es) Composición farmacéutica inhalable que comprende una dispersión de partículas liposomales que contienen un agente bioactivo hidrófobo, tal como coq10, un fosfolípido, y un vehículo de dispersión acuosa, apta para aerosolización continua; método de preparación; método de administración; uso para tratar enfermedades del pulmón.
JP2014532665A5 (enExample)
RU2659729C2 (ru) Кохлеаты, полученные с использованием фосфатидилсерина сои
JP2022043357A (ja) リポソーム組成物および医薬組成物
US20210008198A1 (en) Immunotherapeutic constructs and methods of their use
US20200009050A1 (en) Pharmaceutical composition, preparation and uses thereof
Stillman et al. Aluminum-based metal–organic framework nanoparticles as pulmonary vaccine adjuvants
HRP20230655T1 (hr) Metode liječenja artritisa
JP2017517533A5 (enExample)
JP6705933B2 (ja) リポソーム組成物およびその製造方法
KR20210081256A (ko) 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트
JP6893245B2 (ja) 脂質ナノ粒子用膜材料組成物
CA2854430C (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
JP2022064923A (ja) 癌を治療するための方法および組成物
ES2645076T3 (es) Adyuvante
TW202015703A (zh) 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥
US20230310504A1 (en) Platelet membrane coated nanoparticles and uses thereof
CA3150972A1 (en) Immune stimulating micelle composition
HRP20230985T1 (hr) Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi
US20240358639A1 (en) Nanoparticles for cancer treatment